These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34584583)

  • 81. Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease.
    Lamers CR; de Roos NM; Bongers CCWG; Ten Haaf DSM; Hartman YAW; Witteman BJM; Hopman MTE
    Scand J Gastroenterol; 2021 Jan; 56(1):30-37. PubMed ID: 33211989
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.
    van Rheenen PF; Van de Vijver E; Fidler V
    BMJ; 2010 Jul; 341():c3369. PubMed ID: 20634346
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study.
    Shimoyama T; Yamamoto T; Umegae S; Matsumoto K
    BMC Gastroenterol; 2018 Aug; 18(1):120. PubMed ID: 30068300
    [TBL] [Abstract][Full Text] [Related]  

  • 85. VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study.
    Hasler S; Zahnd N; Müller S; Vavricka S; Rogler G; Tandjung R; Rosemann T
    BMJ Open; 2015 Mar; 5(3):e007306. PubMed ID: 25757949
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis.
    Cypers H; Varkas G; Beeckman S; Debusschere K; Vogl T; Roth J; Drennan MB; Lavric M; Foell D; Cuvelier CA; De Vos M; Delanghe J; Van den Bosch F; Elewaut D
    Ann Rheum Dis; 2016 Jul; 75(7):1357-62. PubMed ID: 26698844
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin.
    Schröder O; Naumann M; Shastri Y; Povse N; Stein J
    Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India.
    Larsson G; Shenoy KT; Ramasubramanian R; Thayumanavan L; Balakumaran LK; Bjune GA; Moum BA
    United European Gastroenterol J; 2014 Oct; 2(5):397-405. PubMed ID: 25360318
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease.
    Røseth AG; Schmidt PN; Fagerhol MK
    Scand J Gastroenterol; 1999 Jan; 34(1):50-4. PubMed ID: 10048733
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease.
    Haisma SM; Verkade HJ; Scheenstra R; van der Doef HPJ; Bodewes FAJA; van Rheenen PF
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):466-473. PubMed ID: 31365486
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: calprotectin and IL-6 changes do not correspond to sRAGE changes.
    Malícková K; Kalousová M; Fucíková T; Bortlík M; Duricová D; Komárek V; Zima T; Janatková I; Lukás M
    Scand J Clin Lab Invest; 2010 Jul; 70(4):294-9. PubMed ID: 20446880
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment.
    Hicks A; Hamlin PJ; Selinger CP
    Inflamm Intest Dis; 2020 Nov; 5(4):191-199. PubMed ID: 33313071
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Accuracy of 99mTc (V)-Dimercaptosuccinic Acid Scintigraphy and Fecal Calprotectin Compared with Colonoscopy in Localizing Active Lesions in Inflammatory Bowel Disease.
    Basirat V; Azizi Z; Javid Anbardan S; Taghizadeh Asl M; Farbod Y; Teimouri A; Ebrahimi Daryani N
    Middle East J Dig Dis; 2016 Jul; 8(3):212-218. PubMed ID: 27698971
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.
    Leach ST; Yang Z; Messina I; Song C; Geczy CL; Cunningham AM; Day AS
    Scand J Gastroenterol; 2007 Nov; 42(11):1321-31. PubMed ID: 17852869
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis.
    Malham M; Carlsen K; Riis L; Paerregaard A; Vind I; Fenger M; Wewer V
    Scand J Gastroenterol; 2019 Oct; 54(10):1214-1219. PubMed ID: 31526273
    [No Abstract]   [Full Text] [Related]  

  • 97. The Effect of Vitamin D on Intestinal Inflammation and Faecal Microbiota in Patients with Ulcerative Colitis.
    Garg M; Hendy P; Ding JN; Shaw S; Hold G; Hart A
    J Crohns Colitis; 2018 Jul; 12(8):963-972. PubMed ID: 29726893
    [TBL] [Abstract][Full Text] [Related]  

  • 98. New Faecal Calprotectin Assay by IDS: Validation and Comparison to DiaSorin Method.
    Castiglione V; Berodes M; Lukas P; Louis E; Cavalier E; Lutteri L
    Diagnostics (Basel); 2022 Sep; 12(10):. PubMed ID: 36292026
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Verification of the Bühlmann fCAL turbo faecal calprotectin assay on the Binding Site Optilite benchtop analyser.
    Handley SA; Dote NP; Wanandy T; Prentice L
    Pract Lab Med; 2023 Aug; 36():e00318. PubMed ID: 37649548
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Promoting early testing and appropriate referral to reduce diagnostic delay for children with suspected inflammatory bowel disease, a narrative review.
    Vernon-Roberts A; Day AS
    Transl Pediatr; 2023 Jul; 12(7):1416-1430. PubMed ID: 37575896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.